Takeda Pharmaceutical Company Limited
TAK
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $58.6B
$18.43
▲ +1.10%
P/E
80.99
Mkt Cap
$58.6B
52-Wk Range
$12.99–$18.90
52-Week Range
$12.99 - $18.90
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 21.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.1).
- High premium - requires strong execution
Growth
Stable outlook
Value
High premium - requires strong execution
Momentum
Hot
+22.6% over 3m
Quality
Excellent
Strong fundamentals
Dividend
Solid
3.43% yield
Smart-money signal
Who's buying TAK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of $0.23 vs $0.17 consensus (+33.2% surprise). Revenue of $7.7B vs $7.1B expected (+7.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+33.2%
Revenue trend · last 1Q
—
Q1 26
$7.7B
Margins · last 1Q
Profit
9.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How TAK stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.